State Initiatives | Association for Accessible Medicines
AAM All Access Podcast - Featuring AAM CEO Dan Leonard and Apotex President and CEO Jeff Watson

State Initiatives

AAM Statement on Maine LD 1117

WASHINGTON DC (June 16, 2021) – “The Association for Accessible Medicines (AAM) strongly encourages the Maine House of Representatives to oppose LD 1117. The fact is generic medicines drive cost savings for patients and increase access to life-saving treatments. According to the Maine Health Data Organization, every one of the 25 most costly prescription drugs in the state is a brand-name drug – none are generic medicines. LD 1117 misdiagnoses the problem of high drug prices and instead would only result in harming patient access to affordable generic medicines.”

Lisa Steelman Joins AAM as Vice President, State Government Affairs

WASHINGTON, DC (August 10, 2020) — Today Lisa Steelman is joining the Association for Accessible Medicines (AAM). As Vice President, State Government Affairs, she serves as a senior strategist and lobbyist in partnership with the Senior Vice President, Government Affairs, Chris Bowlin, and other members of the State Government Affairs team to represent AAM and its member companies’ interests before state legislators, regulators and other state and local governmental entities.

A Generic Summer Savings Tour: How Did Your State Do?

The 11th edition of the Association for Accessible Medicines' annual Access and Savings Report (see summary) reveals how much money American patients and taxpayers saved in 2018 through competition from generic drugs and biosimilar alternatives to brand-name biologic medicines. The report provides data by state, based on findings by IQVIA. We’re releasing a detailed publication later this summer.

Some notable facts from the state data:

Subscribe to State Initiatives

Association for Accessible Medicines


Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.